@kelly_garis's 16-pound tirzepatide loss claim, fact-checked
Quick answer
The creator reports 16 pounds of weight loss over five weeks on self-administered tirzepatide sourced from an unregulated peptide supplier, drawing doses by unit from a vial rather than using a calibrated brand-name pen. She also describes splitting a weekly dose into two injections the prior week, which has no established clinical protocol. The combination of unverified sourcing, unit-based dosing without confirmed vial concentration, and split administration introduces meaningful safety and accuracy concerns that are absent from the clinical trial data on tirzepatide.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @kelly_garis's 16-pound tirzepatide loss claim, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "@kelly_garis's 16-pound tirzepatide loss claim, fact-checked" from Kelly Garis. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator reports 16 pounds of weight loss over five weeks on self-administered tirzepatide sourced from an unregulated peptide supplier, drawing doses by unit from a vial rather than using a calibrated brand-name pen.
The reason this review is not generic is the canonical claim label "glp1 16 lbs down in 5 weeks can t complain tirzepatide glp1." The review points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator reports 16 pounds of weight loss over five weeks on self-administered tirzepatide sourced from an unregulated peptide supplier, drawing doses by unit from a vial rather than using a calibrated brand-name pen.
FormBlends verdict
Compounded Tirzepatide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator reports 16 pounds of weight loss over five weeks on self-administered tirzepatide sourced from an unregulated peptide supplier, drawing doses by unit from a vial rather than using a calibrated brand-name pen. She also describes splitting a weekly dose into two injections the prior week, which has no established clinical protocol. The combination of unverified sourcing, unit-based dosing without confirmed vial concentration, and split administration introduces meaningful safety and accuracy concerns that are absent from the clinical trial data on tirzepatide.
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed average weight loss of 20.9% over 72 weeks at the highest tirzepatide dose, meaning early rapid losses like Kelly's are possible but not typical long-term benchmarks.
- The FDA removed tirzepatide from its drug shortage list in late 2024, which significantly narrows the legal pathway for compounded versions and makes gray-market peptide sourcing even more legally and medically ambiguous.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed average weight loss of 20.9% over 72 weeks at the highest tirzepatide dose, meaning early rapid losses like Kelly's are possible but not typical long-term benchmarks.
- The FDA removed tirzepatide from its drug shortage list in late 2024, which significantly narrows the legal pathway for compounded versions and makes gray-market peptide sourcing even more legally and medically ambiguous.
- Unit-based dosing from unlabeled vials is a documented source of GLP-1 medication errors; the FDA's 2024 compounded GLP-1 safety communication cited hospitalizations tied to this exact dosing format.
- Progesterone in the luteal phase genuinely increases appetite, so Kelly's hunger spike around her period is consistent with established endocrine research, not a sign her medication stopped working.
- Splitting a weekly tirzepatide dose into two injections has no clinical trial support and does not align with the drug's pharmacokinetic design, which relies on a half-life of approximately five days for steady-state efficacy.
- Affiliate discount codes from peptide suppliers represent a financial relationship that viewers should weigh when evaluating whether a creator's endorsement is objective health information or paid promotion.
- Compounded and gray-market tirzepatide products are not bioequivalent to FDA-approved Zepbound or Mounjaro; they carry no guarantees of purity, concentration accuracy, or sterile manufacturing standards.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @kelly_garis actually say?
Kelly says she lost 16 pounds over five full weeks on tirzepatide, is now heading into week six, and injected "16.67 units" of what she calls a peptide from a website called certified-pept.com. She also mentions splitting her weekly dose into two separate shots the prior week and deciding it wasn't worth the extra injection. She's promoting a 15% discount code for that supplier.
A few things immediately stand out. She's not using a brand-name tirzepatide product like Zepbound or Mounjaro. She's drawing up units from what sounds like a vial, which is the hallmark of compounded or gray-market peptide sourcing. She's also openly promoting a third-party supplier with an affiliate code, which is worth flagging for anyone watching this as medical guidance.
Does the science back this up?
The weight loss rate she describes is plausible but sits at the high end of what clinical trials show, especially early on. It is not impossible, but context matters.
The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) is the landmark tirzepatide weight loss study. At the highest dose (15 mg), participants lost an average of 20.9% of body weight over 72 weeks. Early-phase weight loss in that trial was faster, partly because of water weight and rapid appetite suppression in the first few weeks. Losing 16 pounds in five weeks is aggressive but not outside the range of early responders, particularly if someone has significant water retention to shed or was already eating substantially less.
The hunger increase she mentions around her menstrual cycle also has biological backing. Research on hormonal fluctuations and appetite, including work by Davidsen et al. (2007, Acta Obstetricia et Gynecologica Scandinavica), confirms that progesterone in the luteal phase can increase appetite and caloric intake. Her observation here is reasonable.
What did they get wrong (or right)?
She got the hunger-and-cycle connection right. That part is grounded in real physiology.
What she got wrong, or at minimum glossed over, is more serious. She is sourcing tirzepatide from a website called certified-pept.com and calling it a "peptide" rather than a medication. Compounded tirzepatide from licensed compounding pharmacies became legally available during an FDA shortage period, but the FDA has since removed tirzepatide from its shortage list as of late 2024, which changes the legal and safety picture considerably. Gray-market peptide suppliers are a separate category entirely. They operate outside pharmacy regulation, and their products have no guaranteed potency, sterility, or identity verification.
Her dose framing is also problematic. Saying she draws "16.67 units" and rounds up to 17 sounds precise, but units mean different things depending on concentration. Without knowing the vial's concentration, those numbers are meaningless to viewers trying to replicate her dose, and potentially dangerous.
Splitting her weekly dose into two injections is not a standard protocol for tirzepatide, which is designed as a once-weekly injection. There is no published evidence supporting split dosing as a strategy to improve tolerability or efficacy.
What should you actually know?
Tirzepatide is a legitimate, FDA-approved dual GIP and GLP-1 receptor agonist. The clinical evidence for its weight loss effects is strong. But the drug someone buys from a peptide website is not the same product studied in clinical trials, and treating them as equivalent is a mistake.
The FDA has issued warnings about compounded semaglutide and tirzepatide products specifically because of dosing errors and contamination risks. A 2024 FDA safety communication flagged reports of hospitalizations related to compounded GLP-1 products, including cases tied to unit-based dosing confusion.
- Tirzepatide is approved by the FDA as Zepbound (weight management) and Mounjaro (type 2 diabetes) in fixed-dose pens, not vials.
- Purchasing tirzepatide from unregulated peptide suppliers carries real risks: unknown purity, incorrect concentration, and no pharmacist oversight.
- Early weight loss on GLP-1 class drugs often includes water weight and is not fully representative of long-term fat loss trends.
- If you are interested in tirzepatide, the path is through a licensed prescriber and a regulated pharmacy, not a discount code from a TikTok influencer.
Should you take medical cues from this video?
No. Kelly seems genuine, and her experience may be real. But she is not a medical professional, her supplier is unverified, and her dose framing is not replicable in any safe or meaningful way. The 15% discount code is a financial incentive that should make any viewer think twice about how objective this content actually is. Weight loss results on GLP-1 medications vary significantly based on starting weight, dose, adherence, and individual metabolism. Her results are hers. They are not a prediction for anyone else.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Kelly Garis · TikTok creator
135.9K views on this video
16 lbs down in 5 weeks! Can’t complain! #tirzepatide #glp1 #glp1journey
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the evidence say about surmount-1 (jastreboff et al., 2022, nejm) showed average weight loss?
SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed average weight loss of 20.9% over 72 weeks at the highest tirzepatide dose, meaning early rapid losses like Kelly's are possible but not typical long-term benchmarks.
What does the evidence say about the fda removed tirzepatide from its drug shortage list in?
The FDA removed tirzepatide from its drug shortage list in late 2024, which significantly narrows the legal pathway for compounded versions and makes gray-market peptide sourcing even more legally and medically ambiguous.
What does the evidence say about unit-based dosing from unlabeled vials?
Unit-based dosing from unlabeled vials is a documented source of GLP-1 medication errors; the FDA's 2024 compounded GLP-1 safety communication cited hospitalizations tied to this exact dosing format.
What does the evidence say about progesterone in the luteal phase genuinely increases appetite, so kelly's?
Progesterone in the luteal phase genuinely increases appetite, so Kelly's hunger spike around her period is consistent with established endocrine research, not a sign her medication stopped working.
What does the evidence say about splitting a weekly tirzepatide dose into two injections has no?
Splitting a weekly tirzepatide dose into two injections has no clinical trial support and does not align with the drug's pharmacokinetic design, which relies on a half-life of approximately five days for steady-state efficacy.
What does the evidence say about affiliate discount codes from peptide suppliers represent a financial relationship?
Affiliate discount codes from peptide suppliers represent a financial relationship that viewers should weigh when evaluating whether a creator's endorsement is objective health information or paid promotion.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Kelly Garis, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.